Subthalamic beta band suppression reflects effective neuromodulation in chronic recordings.

Feldmann LK, Neumann WJ, Krause P, Lofredi R, Schneider GH, Kühn AA.
Eur J Neurol.


Background and purpose

Biomarkers for future adaptive deep brain stimulation still need evaluation in clinical routine. Here, we aimed to assess stimulation-induced modulation of beta-band activity and clinical symptoms in a Parkinson’s disease patient during chronic neuronal sensing using a novel implantable pulse generator.


Subthalamic activity was recorded OFF and ON medication during a stepwise increase of stimulation amplitude. Off-line fast fourier transfom -based analysis of beta-band activity was correlated with motor performance rated from blinded videos.


The stepwise increase of stimulation amplitude resulted in decreased beta oscillatory activity and improvement of bradykinesia. Mean low beta-band (13–20 Hz) activity correlated significantly with bradykinesia (ρ = 0.662, p < 0.01).


Motor improvement is reflected in reduced subthalamic beta-band activity in Parkinson’s disease, supporting beta activity as a reliable biomarker. The novel PERCEPT neurostimulator enables chronic neuronal sensing in clinical routine. Our findings pave the way for a personalized precision-medicine approach to neurostimulation.

Published: Mar 2021